BioNTech Shares Gain 11% on Filing COVID-19 Vaccine Expanded Use Request to EMA in Children Ages 12 to 15

May 4, 2021

Source: Streetwise Reports   05/03/2021

BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine.

Germany-based biotechnology company Biopharmaceutical New Technologies SE “BioNTech” (BNTX:NASDAQ) and global pharmaceutical firm Pfizer Inc. (PFE:NYSE) announced that they have “submitted a variation to the Conditional Marketing Authorization (CMA) in the European Union (EU) to the European Medicines Agency (EMA) for the Pfizer-BioNTech vaccine COMIRNATY® (BNT162b2) to request an extension of the indication for use in adolescents 12 to 15 years of age.”

The companies noted that in the event that the EMA grants approval for expanded use for these lower age groups, then the amended use authorization will be valid in each of the 27 EU member states.


Get our Weekly Commitment of Traders Reports: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.




Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter






The report advised that BioNTech and Pfizer have previously submitted a request the U.S. Food and Drug Administration (FDA) for the Emergency Use Authorization (EUA), which was virtually similar to that filed with the EMA, and that the two firms intend to file additional requests as needed with other worldwide regulatory governing authorities.

The companies reported that the expanded use submission was based upon the data from a pivotal Phase 3 clinical trial that enrolled a total of 2,260 individuals between the ages of 12 to 15. The firms pointed out that the topline data from this trial were announced at the end of March 2021 and indicated that the results demonstrated “a vaccine efficacy of 100% in participants with or without prior SARS-CoV-2 infection and robust antibody responses.”

The report stated that the Pfizer-BioNTech COVID-19 vaccine was jointly developed by BioNTech and Pfizer and was based upon BioNTech’s proprietary mRNA technology.

Pfizer is a global research-based biopharmaceutical company based in New York. The firm is active in the discovery, development and manufacture of healthcare products. Its global medicine portfolio is composed of many well-known brand prescription medications including Celebrex, Eliquis, Lipitor, Prevnar 13, Xeljanz, Pristiq and Viagra. The firm’s shares trade on the NYSE and it has a market cap of about $215 billion.

Coronavirus

BioNTech is headquartered in Mainz, Germany, and concentrates its efforts on providing next generation immunotherapies for cancer and other serious diseases. The firm noted that “its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.” Along with its oncology pipeline, the company is utilizing its strong expertise in mRNA vaccine development and manufacturing capabilities to create multiple mRNA vaccine candidates for infectious diseases. In addition to its close work with Pfizer on its mRNA-based COVID-19 vaccine, the company also partners and collaborates with many other leading pharmaceutical firms including Bayer Animal Health, Fosun Pharma, Genevant, Genmab, Regeneron, Sanofi and Genentech, which is a member of the Roche Group.

BioNTech started the week with a market capitalization of around $45.5 billion with approximately 241.50 million shares outstanding. BNTX shares opened more than 7% higher today at $202.25 (+$13.97, +7.42%) over Friday’s $188.28 closing price reached a new 52-week high price today of $211.65. The firm’s U.S. ADR shares have traded today between $196.00 to $211.65 per share and closed for trading at $208.90 (+$20.62, +10.95%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.